Overview
Permanent neonatal diabetes mellitus (PNDM) is a rare form of diabetes diagnosed in the first six months of life, characterized by insulin deficiency due to mutations in genes encoding for ATP-sensitive potassium channels, such as Kir6.2 (KCNJ11). 1Diagnosis
Genetic testing for mutations in KCNJ11 and ABCC8 genes is essential for diagnosis.
Elevated blood glucose levels confirmed by repeat testing.
Exclusion of transient neonatal diabetes mellitus through clinical and genetic criteria.
Electrolyte imbalances and ketoacidosis may be present but are not exclusive to PNDM.Management
First-line treatment: Insulin therapy to manage hyperglycemia.
Adjunctive treatment: Sulfonylureas (e.g., glibenclamide) may be effective in patients with KCNJ11 mutations, potentially reducing or eliminating the need for insulin. 1
Close monitoring of glycemic control and growth parameters in pediatric patients.Special Populations
Pediatrics: Early initiation of appropriate therapy is crucial for normal growth and development. 1
Comorbidities: Patients with specific mutations like I296L may present with additional neurological symptoms (developmental delay, muscle weakness, epilepsy), requiring multidisciplinary care. 1Key Recommendations
Genetic testing should be performed to identify specific mutations in KCNJ11 and ABCC8 genes for accurate diagnosis and tailored management. (Evidence: Strong 1)
Consider sulfonylurea therapy in patients with PNDM due to KCNJ11 mutations to potentially reduce insulin dependency. (Evidence: Moderate 1)
Regular monitoring of both metabolic control and neurological development is essential, especially in patients with associated developmental issues. (Evidence: Expert opinion 1)References
1 Proks P, Girard C, Haider S, Gloyn AL, Hattersley AT, Sansom MS et al.. A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO reports 2005. link